- American City Business Journals•15 hours ago
GlaxoSmithKline said Monday it has submitted a biologics license application with the Food and Drug Administration seeking approval for its experimental shingle vaccine. Analysts have projected the new drug candidate, called Shingrix, could develop into a $1 billion a year product — if it receives regulatory approval. Shingles is an acute and painful inflammation of nerve cells that occurs as a result of reactivation of latent chickenpox virus.
- Reuters•23 hours ago
GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, the drugmaker said on Monday, bringing the potential $1 billion-a-year seller a step closer to market. Shingrix is viewed by analysts as among the British company's most promising experimental products, since it has shown greater protection among older recipients than Merck & Co's rival shot Zostavax. The company, which will see Emma Walmsley take over as chief executive in 2017, is seeking to revitalise a drug portfolio hit by falling sales of best-selling inhaled lung treatment Advair.
GlaxoSmithKline said on Monday it had filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential blockbuster a step closer to market. Shingrix is viewed by analysts as among ...
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
|Bid||1,637.00 x 175400|
|Ask||1,675.00 x 417900|
|Day's Range||1,640.67 - 1,670.00|
|52wk Range||1,277.25 - 1,745.56|
|1y Target Est||N/A|
|P/E Ratio (ttm)||2,735.00|
|Avg Vol (3m)||7,753,806|
|Dividend & Yield||N/A (N/A)|